Oruka Therapeutics Inc

Oruka Therapeutics’ finance chief’s buy‑then‑sell insider moves hint at confidence in the biotech’s pipeline, offering investors a potential bullish signal amid recent price swings.

Oruka’s CMO buys 7,000 shares amid a $31.8M loss, showing confidence in upcoming heart‑failure milestones while highlighting dilution risks.

Oruka Therapeutics insider moves reveal a balanced strategy—COO buys at $7.80 while executing planned Rule 10b5‑1 sales at $62‑$67, signaling confidence but caution as the biotech heads toward heart‑failure milestones.

Oruka insider Joana’s buy‑sell pattern shows disciplined long‑term confidence, boosting investor optimism as analysts upgrade the stock and institutional buying rises.